CELLULAR INTERACTIONS RESPONSIBLE FOR DEVELOPMENT, MAINTENANCE, AND STRENGTH OF THE SKELETON
With
Prof Natalie A Sims, PhD.
Deputy Director, St. Vincent’s Institute,
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | May 2025
Professor Sims directs the Bone Cell Biology and Disease Unit at St. Vincent’s Institute of Medical Research and is a Professorial Fellow at The University of Melbourne and Australian Catholic University.
She leads a team who studies the cellular interactions responsible for development, maintenance, and strength of the skeleton. She completed her PhD at the University of Adelaide, followed by postdoctoral work at the Garvan Institute in Sydney then at Yale School of Medicine, in New Haven, Connecticut, where she studied the role of the estrogen receptor in regulating bone structure.
She returned to Australia in 2001 to set up a laboratory at St. Vincent’s Hospital and SVI. Her laboratory studies the cellular interactions responsible for development, maintenance, and strength of the skeleton, including the IL-6 family of cytokines, using genetically altered mouse models, in vitro system and human specimens. She has published more than 140 peer reviewed original research articles, 48 peer reviewed review articles and commentaries, and 20 published chapters; H index of 64 (Scopus); more than 13,500 career citations.
Her work has been recognised by awards from her colleagues internationally, including the International Bone and Mineral Society Herbert A Fleisch Award (2013) and the American Society of Bone and Mineral Research (ASBMR) Fuller Albright Award (2010) and Paula Stern Award (2020).
She is a Deputy Editor of the Journal of Bone and Mineral Research and serves on the Editorial Board of the Journal of Biological Chemistry. She has served as President of the Australia and New Zealand Bone and Mineral Society and is currently Executive Secretary of the International Federation of Musculoskeletal Research Societies.
Source: Supplied
-
Oral administration of insulin for Type 1 Diabetes
Huiwen Pang is a 3rd year PhD candidate in the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, focusing on biomedical health research. Prior to commencing his PhD, Huiwen studied animal genetics in his Masters degree at Huazhong Agriculture University in China.
People with diabetes, especially Type 1 diabetes, largely rely on the insulin injections or insulin pumps to control their high blood glucose levels, which is painful and has a high risk of infections.
Huiwen Pang is conducting research on nano-based drug formulations for Type 1 diabetes treatment, with a focus on using nanomaterials to load insulin for oral administration and employing anti-apoptotic and anti-inflammatory approaches to mitigate damage to beta cells.
-
Novel immunotherapies in lymphoma
Dr Sean Harrop is a dual-trained haematologist having completed his clinical and laboratory haematology training at the Peter MacCallum Cancer Centre, Royal Melbourne Hospital and St Vincent’s Hospital Melbourne. He is the current clinical haematology fellow (aggressive lymphoma) at Peter MacCallum and a PhD student in the Cancer Immunology Program in the Neeson Lab.
-
Stem cell therapies for enteric neuropathies
Dr Stamp is a Group Leader in the Department of Anatomy and Physiology at the University of Melbourne, Australia. Dr Stamp’s PhD research (with Prof Martin Pera, Monash University) focused on the derivation of hepatopancreatic progenitors from human embryonic stem cells. He then joined the lab of Dr Don Newgreen at the Murdoch Childrens Research Institute where he began working on development of the enteric nervous system (ENS), before joining Prof Heather Young’s lab at the University of Melbourne, where he focused on developing a stem cell therapy to treat gut motility disorders such as the paediatric enteric neuropathy Hirschprung disease.
